|
|
 |
|
Viewing report
|
|
|
|
Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants
Datamonitor, June 2011, Pages: 199
Introduction
Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival of more effective and less invasive treatment options after numerous years of limited therapeutic options. As competition intensifies, the need for less invasive modes of administration will be met and new drugs will have to compete on other factors, such as efficacy.
Features and benefits
- Understand The independent appraisal of marketed brands and key pipeline agents indicated for treating multiple sclerosis.
- Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.
- Assessment of the strengths, weaknesses, opportunities, and threats for key marketed and pipeline therapies.
- Review of important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
- Determine to what extent current and future therapies satisfy the main clinical unmet needs in multiple sclerosis treatment.
Highlights
The recent survey reveals that US neurologists prescribe Gilenya because of its strong efficacy in treatment resistant patients as well as its convenient oral mode of administration. However, long term cancer and infection risk remain the main concerns.
The multiple sclerosis market has been lucrative for drug companies over the last decade with limited competition and periodic price increases. However, as this dynamic is changing with increased competition, existing players are expanding their portfolios with new and improved therapies.
Monoclonal antibodies have demonstrated potent efficacy in Phase II trials, surpassing all existing therapies. However, excitement is tempered with safety concerns that include risk of malignancy and severe infections. Still, as seen with Tysabri, impressive efficacy may outweigh the risks for more severe multiple sclerosis patients.
Your key questions answered
- How well do agents in late-stage development for multiple sclerosis compare to one another and the current standard of care?
- What is the most promising treatment in development for multiple sclerosis?
- How do US neurologists perceive Gilenya and key pipeline agents as new treatments of multiple sclerosis?
|
|
|
|
